{"id":"https://openalex.org/W4416844628","doi":"https://doi.org/10.1158/1078-0432.30750607","title":"Supplementary Figure S5 from A First-in-Class mAb (BI-1607) Targeting Fc\u03b3RIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors","display_name":"Supplementary Figure S5 from A First-in-Class mAb (BI-1607) Targeting Fc\u03b3RIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors","publication_year":2025,"publication_date":"2025-12-01","ids":{"openalex":"https://openalex.org/W4416844628","doi":"https://doi.org/10.1158/1078-0432.30750607"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.30750607","doi":"https://doi.org/10.1158/1078-0432.30750607","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30750607","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750607/1/files/59994319.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750607/1/files/59994319.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5051629490","display_name":"Javier Cort\u00e9s","orcid":"https://orcid.org/0000-0001-7623-1583","observed_orcids":["https://orcid.org/0000-0001-7623-1583"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Javier Cort\u00e9s","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7623-1583","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091608801","display_name":"Araceli Priego","orcid":"https://orcid.org/0009-0003-3441-1609","observed_orcids":["https://orcid.org/0009-0003-3441-1609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Araceli Priego","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0003-3441-1609","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059711568","display_name":"Elena Garralda","orcid":"https://orcid.org/0000-0002-4412-7842","observed_orcids":["https://orcid.org/0000-0002-4412-7842"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Elena Garralda","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4412-7842","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041559941","display_name":"Katerin Rojas","orcid":"https://orcid.org/0009-0003-4261-8597","observed_orcids":["https://orcid.org/0009-0003-4261-8597"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Katerin Rojas","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0003-4261-8597","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085866945","display_name":"Simon Lord","orcid":"https://orcid.org/0000-0001-7946-5609","observed_orcids":["https://orcid.org/0000-0001-7946-5609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Simon R. Lord","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-7946-5609","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076298207","display_name":"Thorsten Oliver Goetze","orcid":"https://orcid.org/0000-0002-8633-2748","observed_orcids":["https://orcid.org/0000-0002-8633-2748"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Thorsten O. Goetze","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8633-2748","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054650117","display_name":"Sherko K\u00fcemmel","orcid":"https://orcid.org/0000-0001-9355-494X","observed_orcids":["https://orcid.org/0000-0001-9355-494X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sherko Kuemmel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-9355-494X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078099654","display_name":"Simon J. Crabb","orcid":"https://orcid.org/0000-0003-3521-9064","observed_orcids":["https://orcid.org/0000-0003-3521-9064"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Simon J. Crabb","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3521-9064","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082956749","display_name":"Zinnia Patricia Parra-Guillen","orcid":"https://orcid.org/0000-0003-1503-2710","observed_orcids":["https://orcid.org/0000-0003-1503-2710"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zinnia P. Parra-Guillen","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1503-2710","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007108884","display_name":"Marie Borggren","orcid":"https://orcid.org/0009-0001-0346-1676","observed_orcids":["https://orcid.org/0009-0001-0346-1676"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marie Borggren","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0001-0346-1676","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065612884","display_name":"Ingrid Karlsson","orcid":"https://orcid.org/0009-0006-2466-919X","observed_orcids":["https://orcid.org/0009-0006-2466-919X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ingrid Karlsson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-2466-919X","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5119942444","display_name":"Danijela Lindahl","orcid":"https://orcid.org/0009-0004-4557-3483","observed_orcids":["https://orcid.org/0009-0004-4557-3483"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danijela Lindahl","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0004-4557-3483","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108728970","display_name":"Linda M\u00e5rtensson","orcid":"https://orcid.org/0009-0002-9518-7359","observed_orcids":["https://orcid.org/0009-0002-9518-7359"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Linda M\u00e5rtensson","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0002-9518-7359","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045250854","display_name":"Robert J. Oldham","orcid":"https://orcid.org/0000-0002-8007-1145","observed_orcids":["https://orcid.org/0000-0002-8007-1145"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robert Oldham","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-8007-1145","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025722647","display_name":"Anna Ropenga","orcid":"https://orcid.org/0009-0000-6934-1741","observed_orcids":["https://orcid.org/0009-0000-6934-1741"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Anna Ropenga","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0000-6934-1741","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049258782","display_name":"Ingrid Teige","orcid":"https://orcid.org/0009-0007-5996-3396","observed_orcids":["https://orcid.org/0009-0007-5996-3396"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ingrid Teige","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0007-5996-3396","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056353703","display_name":"Johan Erik Wallin","orcid":"https://orcid.org/0000-0002-4143-0096","observed_orcids":["https://orcid.org/0000-0002-4143-0096"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Johan Wallin","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-4143-0096","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013771543","display_name":"Bj\u00f6rn Frend\u00e9us","orcid":"https://orcid.org/0000-0003-3177-8686","observed_orcids":["https://orcid.org/0000-0003-3177-8686"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bj\u00f6rn Frendeus","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3177-8686","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5000250788","display_name":"Andr\u00e9s McAllister","orcid":"https://orcid.org/0009-0006-5510-444X","observed_orcids":["https://orcid.org/0009-0006-5510-444X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Andres McAllister","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0009-0006-5510-444X","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9301999807357788,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.9301999807357788,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.0632999986410141,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fcgammariib","display_name":"Fc\u03b3RIIB","score":0.9620000123977661},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.9179999828338623},{"id":"https://openalex.org/keywords/her2-positive-solid-tumors","display_name":"HER2-positive solid tumors","score":0.7509999871253967},{"id":"https://openalex.org/keywords/cytokine-production","display_name":"cytokine production","score":0.9860000014305115},{"id":"https://openalex.org/keywords/peripheral-blood-mononuclear-cells","display_name":"peripheral blood mononuclear cells","score":0.9240000247955322},{"id":"https://openalex.org/keywords/cytokine-profiling","display_name":"cytokine profiling","score":0.4659999907016754},{"id":"https://openalex.org/keywords/first-in-human-safety","display_name":"first-in-human safety","score":0.5019999742507935}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7447999715805054},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.67330002784729},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.6682999730110168},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.511900007724762},{"id":"https://openalex.org/C137061746","wikidata":"https://www.wikidata.org/wiki/Q736033","display_name":"Peripheral blood mononuclear cell","level":3,"score":0.5109999775886536},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4424000084400177},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.42179998755455017},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.36800000071525574},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.32820001244544983},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31790000200271606},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.30970001220703125},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.30720001459121704},{"id":"https://openalex.org/C99476002","wikidata":"https://www.wikidata.org/wiki/Q42297","display_name":"Analysis of variance","level":2,"score":0.3052999973297119},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.29499998688697815},{"id":"https://openalex.org/C163864487","wikidata":"https://www.wikidata.org/wiki/Q6901461","display_name":"Monoclonal","level":4,"score":0.2874000072479248},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.27480000257492065},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.2712000012397766},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.2513999938964844}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1158/1078-0432.30750607","doi":"https://doi.org/10.1158/1078-0432.30750607","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30750607","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750607/1/files/59994319.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/30750607","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750607","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.30750607","doi":"https://doi.org/10.1158/1078-0432.30750607","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.30750607","pdf_url":"https://aacr.figshare.com/articles/journal_contribution/Supplementary_Figure_S5_from_A_First-in-Class_mAb_BI-1607_Targeting_Fc_RIIB_Preclinical_Data_and_First-in-Human_Studies_in_Patients_with_HER2-Positive_Advanced_Solid_Tumors/30750607/1/files/59994319.pdf","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":false},"content_urls":{"pdf":"https://content.openalex.org/works/W4416844628.pdf"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4415045955","https://openalex.org/W4416848322","https://openalex.org/W6976977420","https://openalex.org/W2117021072","https://openalex.org/W2587532658","https://openalex.org/W4377564116","https://openalex.org/W1994406227","https://openalex.org/W2583679698","https://openalex.org/W4248168297","https://openalex.org/W4414101660"],"abstract_inverted_index":{"Figure":[0],"S5:":[1],"Cytokine":[2],"release":[3],"in":[4,12,25,35,41],"high":[5],"density":[6],"cell":[7],"culture.":[8],"1x105":[9],"PBMCs":[10],"resuspended":[11],"fresh":[13],"serum":[14],"free":[15],"CTL-Test":[16],"media":[17],"were":[18,45],"stimulated":[19],"with":[20,57],"10":[21],"\u03bcg/mL":[22],"antibody":[23],"added":[24],"solution":[26],"to":[27,63],"the":[28,42],"cells":[29],"for":[30,77],"24":[31],"hours":[32],"at":[33],"37\u00b0C":[34],"5%":[36],"CO2.":[37],"The":[38],"cytokine":[39],"levels":[40],"culture":[43],"supernatant":[44],"measured":[46],"using":[47],"a":[48],"7-plex":[49],"customized":[50],"MSD":[51],"plate.":[52],"A":[53],"paired":[54],"one-way":[55],"ANOVA":[56],"Tukey\u2019s":[58],"multiple":[59],"comparison":[60],"was":[61],"used":[62],"determine":[64],"significance;":[65],"*":[66],"=":[67,70],"p<0.05;":[68],"ns":[69],"not":[71],"significant.":[72],"Lines":[73],"indicate":[74],"mean":[75],"values":[76],"each":[78,80],"cytokine;":[79],"dot":[81],"is":[82],"indicative":[83],"of":[84],"an":[85],"individual":[86],"healthy":[87],"donor":[88],"(n=6).":[89]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2025-12-01T00:00:00"}